Here are three quick facts.
1. Seven analysts rated the company’s stock as “buy,” seven rated it as “outperform,” and 11 rated it as “hold.”
2. Analysts have a consensus estimate of $0.88 per share.
3. Some Thomas/First Call analysts projected a price target of $71, which would be a 31 percent upside potential from the closing price of $54.04.
More articles on devices:
Plaintiffs win $502M verdict against Johnson & Johnson over hip device — 5 things to know
Touch Surgery, Zimmer Biomet launch Oxford Partial Knee training — 4 points
Life Spine sales jump 45% in 6 months: 5 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
